Men with advanced prostate cancer taking abiraterone or enzalutamide plus hormone therapy were at higher risk of serious medical issues than their peers undergoing hormone therapy alone.
Mary Clare Fischer
Fischer promotes innovations in clinical care and tells patient stories on behalf of the Rogel Cancer Center while also managing external communications for Michigan Medicine’s surgery and urology departments and the Transplant Center. Before joining the university, she spent six years as a journalist. She has a passion for elevating translational research, highlighting the human element of science, and using a lens of diversity, equity and inclusion to shape her storytelling.
Bradley Zebrack reflects on the insights he’s applied from his cancer journey to his job.
Two surgeons-in-training suggest some sustainable solutions for their energy-intensive discipline.
Artificial intelligence helps physicians better assess the effectiveness of bladder cancer treatment
After consulting with a machine learning tool, providers were able to more accurately determine whether patients had a complete response to chemotherapy.
Repaired hernias redeveloped more than 15% of the time in older Americans.